Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
During the mean observation period of 3.3 years, semaglutide at 2.4 mg per week resulted in a mean weight loss of 9.39% from baseline and a 20% reduction in the risk of MACE (HR 0.80, 95% CI 0.720.90), especially a 28% reduction in the risk of myocardial infarction (HR 0.72, 95% CI 0.610.85), compared with that in the placebo group
Which GLP-1 RAs are currently available
J Mol Cell Cardiol 28:667678
It acts at very low doses without toxicity
US$ 22.74
US$ 24.27
US$ 26.63
US$ 26.71
US$ 22.35
